Peptide derived from RAGE efficiently improves oocyte development through attenuating oxidative stress in oocytes of mice with polycystic ovary syndrome

Abstract

Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder in reproductive‐aged women that frequently leads to infertility due to poor oocyte quality. In this study, we identified a new active peptide (advanced glycation end products receptors RAGE344‐355) from PCOS follicular fluid using mass spectrometry. We found that supplementing PCOS‐like mouse oocytes with RAGE344‐355 attenuated both meiotic defects and oxidative stress levels, ultimately preventing developmental defects. Additionally, our results suggest that RAGE344‐355 may interact with eEF1a1 to mitigate oxidative meiotic defects in PCOS‐like mouse oocytes. These findings highlight the potential for further clinical development of RAGE344‐355 as a potent supplement and therapeutic option for women with PCOS. This research addresses an important clinical problem and offers promising opportunities for improving oocyte quality in PCOS patients.